It has been shown that TNF-α acts through the TNF-α-JNK1 axis to inhibit the effects of FGF21 in AT, suggesting that a combination of FGF21 and JNK1 inhibitors could be a potential therapeutic strategy in obesity (319). This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.